Riverview Capital Advisers’s Pfizer PFE Stock Holding History

Riverview Capital Advisers’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-26,708	Closed	-$886K	–	85
2023 Q3	$886K	Sell	26,708 -200	-0.7%	-$7.07K	0.39%	56
2023 Q2	$987K	Buy	26,908 +1,085	+4%	+$42.2K	0.43%	51
2023 Q1	$1.05M	Buy	25,823 +43	+0.2%	+$1.86K	0.45%	50
2022 Q4	$1.32M	Buy	25,780 +33	+0.1%	+$1.58K	0.71%	34
2022 Q3	$1.13M	Buy	25,747 +36	+0.1%	+$1.75K	0.71%	42
2022 Q2	$1.35M	Buy	25,711 +238	+0.9%	+$12.1K	0.75%	39
2022 Q1	$1.32M	Buy	25,473 +941	+4%	+$48.8K	0.61%	40
2021 Q4	$1.45M	Buy	+24,532	New	+$1.22M	0.64%	39

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Riverview Capital Advisers's PFE Position: Q4 2023 in Review

Riverview Capital Advisers sold out of Pfizer (PFE) in Q4 2023, closing a stake of 26,708 shares — an estimated $886K sold.

Riverview Capital Advisers first reported a position in PFE in Q4 2021 and held it in 8 quarters. The position peaked at $1.45M in Q4 2021. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

Riverview Capital Advisers reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
Riverview Capital Advisers sold 26,708 Pfizer shares in Q4 2023, an estimated $886K.
Riverview Capital Advisers first reported a position in Pfizer in Q4 2021 and held it in 8 quarters.
Riverview Capital Advisers's Pfizer position peaked at $1.45M in Q4 2021.
2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on Riverview Capital Advisers's 13F filing for Q4 2023, filed 12 Feb 2024.